Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Bibliographic Details
Main Authors:	Zhang, Shaohua, Li, Lei, Wang, Tao, Bian, Li, Hu, Haixu, Xu, Chunhong, Liu, Bing, Liu, Yi, Cristofanilli, Massimo, Jiang, Zefei
Format:	Online
Language:	English
Published:	BioMed Central 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960713/

Similar Items

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
by: Liu, Yi, et al.
Published: (2013)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
by: Fehm, Tanja, et al.
Published: (2007)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
by: Lipton, Allan, et al.
Published: (2013)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor1
by: Beije, Nick, et al.
Published: (2016)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
by: Mu, Zhaomei, et al.
Published: (2014)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
by: Stenehjem, David D, et al.
Published: (2014)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Ishimine, Yu, et al.
Published: (2015)

Comparison between Real-Time Quantitative PCR Detection of HER2 mRNA Copy Number in Peripheral Blood and ELISA of Serum HER2 Protein for Determining HER2 Status in Breast Cancer Patients
by: Savino, Maria, et al.
Published: (2009)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
by: Han, Sae-Won, et al.
Published: (2012)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
by: Spector, Neil, et al.
Published: (2007)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
by: Lollini, Pier-Luigi, et al.
Published: (2013)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
by: Vicario, Rocio, et al.
Published: (2015)

Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma
by: Dai, Shu-Qin, et al.
Published: (2013)

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
by: Bozzetti, C, et al.
Published: (2011)

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
by: Bozzetti, C, et al.
Published: (2011)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
by: Dent, S., et al.
Published: (2009)

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
by: Gómez-Martin, Carlos, et al.
Published: (2012)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
by: Chandran, Vineesh Indira, et al.
Published: (2015)

HER2 status and disparities in luminal breast cancers
by: Holowatyj, Andreana N., et al.
Published: (2016)

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
by: Seo, An Na, et al.
Published: (2014)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
by: Laidi, Fatna, et al.
Published: (2014)

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
by: Soares, Maria, et al.
Published: (2016)

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis
by: Yu, Qiuyan, et al.
Published: (2015)

HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study
by: Huang, Dan, et al.
Published: (2013)

Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis
by: Zhang, Kecheng, et al.
Published: (2015)

HER-3 expression in HER-2-amplified breast carcinoma
by: Czopek, Jacek, et al.
Published: (2013)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
by: Styczen, Hanna, et al.
Published: (2015)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
by: Ferreira, Renan Barroso, et al.
Published: (2015)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
by: Shankaran, Harish, et al.
Published: (2013)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
by: Yardley, D A, et al.
Published: (2014)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
by: Hosonaga, Mari, et al.
Published: (2014)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
by: Kurozumi, Sasagu, et al.
Published: (2016)

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
by: Hu, Zexi, et al.
Published: (2015)

Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer
by: Li, Jianzong, et al.
Published: (2016)

Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer
by: Chen, Ming, et al.
Published: (2014)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
by: Qin, Tao, et al.
Published: (2013)

HER2-positive gastric cancer
by: Boku, Narikazu
Published: (2013)

Update on HER2-directed therapy
by: Slamon, D
Published: (2005)

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
by: Shin, Daniel Sanghoon, et al.
Published: (2016)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
by: Green, Andrew R., et al.
Published: (2014)